Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600028 · ClinicalTrials.gov registry record · Phase 3
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
A Phase 3 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
NCT00600028: Completed Phase 3 study, sponsored by Johns Hopkins University.
NCT00600028 is a Phase 3 study that has completed, run by Johns Hopkins University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600028, a Phase 3 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
Study Summary
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough. The etiology of the cough associated with IPF is unclear but it is often so severe that it adversely effects the patient's quality of life. We propose that thalidomide specifically suppresses the cough associated with idiopathic pulmonary fibrosis via its anti-inflammatory properties, by suppressing the excessive functional up-regulation of sensory fibers with in the respiratory tract of patients with IPF. This study is a Phase III, double blinded, randomized, placebo controlled, crossover trial testing the efficacy of thalidomide in suppressing the chronic cough of IPF. The primary objective of this study is to determine the efficacy of thalidomide administered daily for 12 weeks to suppress the chronic cough in patients with idiopathic pulmonary fibrosis as measured by cough specific questionnaires, scales and improved quality of life.
Interventions
- DRUG Placebo
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600028
The ClinicalTrials.gov registry entry for NCT00600028 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00600028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600028 about?
NCT00600028 is a clinical study titled "Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide". Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough. The etiology of the cough associated with IPF is unclear but it is often so severe that it adversely effects the patient's quality of life. We propose that thalidomi...
What is the current status of trial NCT00600028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2007-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00600028?
The interventions under investigation include: Placebo (DRUG), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00600028?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.